Deal Wave Led by EQT-QIAGEN and Cencora-American Oncology Network
EQT agreed to buy QIAGEN in an all-cash transaction valued at €10.8 billion, while Cencora reached a $2.4 billion deal for American Oncology Network. NVIDIA secured $1.3 billion in advanced chip packaging capacity from Amkor, and several banks, insurers, and industrial companies announced dividends or buybacks. The session also included real estate financings and leadership changes.
The session’s largest announced transaction was EQT’s all-cash purchase of QIAGEN, valued at €10.8 billion, which would take a diagnostics company private. Cencora separately agreed to pay $2.4 billion for American Oncology Network, extending its reach in cancer-care services.
In technology, Amkor committed $1.3 billion of capacity in Korea for NVIDIA’s advanced packaging needs. Elsewhere, Integer shareholders backed Armstrong’s $4.7 billion purchase, Vornado closed a $3.3 billion loan for 350 Park Avenue with Citadel and Rudin, and UDR and Apollo planned a $2 billion apartment venture.
The QIAGEN and American Oncology Network deals could affect patients and clinicians through changes in ownership of diagnostics and cancer-care services, while employees may face restructuring. Large infrastructure and real-estate financings may influence local development and housing costs. Consolidation may shape bargaining power and service availability, but outcomes depend on regulators, integration, and market conditions.